Adipocyte dysfunction

Adipocyte dysfunction, or adiposopathy, is a pathological state of adipose tissue characterized by hypertrophic adipocytes, impaired lipid buffering, and dysregulated endocrine activity (Source: PubMed PMID: 21210743). This condition often arises during chronic positive energy balance, where expanded fat cells become hypoxic and stressed, leading to the recruitment of macrophages and the onset of chronic low-grade inflammation (Source: NIH/NCBI Bookshelf). Consequently, there is a marked decrease in the secretion of insulin-sensitizing adipokines like adiponectin and an increase in pro-inflammatory factors such as TNF-alpha and IL-6 (Source: J Clin Endocrinol Metab, 2004). This molecular shift promotes systemic insulin resistance, dyslipidemia, and the ectopic deposition of lipids in organs like the liver and skeletal muscle. While 'adipocyte dysfunction' is a descriptive clinical and physiological state rather than a single molecular target, it is the primary focus of metabolic therapies. Drugs like thiazolidinediones address this state by activating PPAR-gamma to restore proper adipocyte differentiation and lipid storage capacity (Source: StatPearls). Understanding the transition from healthy to dysfunctional adipose tissue is critical for managing obesity-related metabolic disorders.

Other names

AdiposopathySick fatAdipose tissue dysfunctionDysfunctional adipose tissue

Drugs do not target 'adipocyte dysfunction' itself but rather specific molecular components involved in the process, such as Peroxisome proliferator-activated receptor gamma (PPARG) to improve insulin sensitivity and promote healthy lipid sequestration, or GLP-1 receptors to reduce systemic inflammation and appetite (Source: PubMed PMID: 23512250, 30335470).